Manuel Gomes David

Gyn onco & Breast surgeon @icl_lorraine @Univ_Lorraine

[Manuel Gomes David @m_gdavid]

I would like to thank Julia Salleron, Pr Frédéric Marchal and all members from @PSOGI_EC and BIGRENAPE groups for the work! @BMCSurgery
#HIPEC #EndometrialCancer #surgery
https://t.co/p35OGcWff2

[Erman Akkus @Erman_Akkus]

🧬Cancer types and genes associated with germline mutations 👇
@ASCO

@OncoAlert @JCOPO_ASCO #cancer #oncology #genetics #MedX

[Mario M. Leitao, Jr @leitaomd]

Interesting

[DrKatyMoore @DrKatyMoore]

ATALANTE OS: I'm going to respectfully disagree with the messaging of this presentation. This was a negative trial. PFS was negative. A "clinically meaningful" OS benefit does not make this a positive trial nor should encourage use of CPI in ovarian cancer. If anything - ATHENA and JAVELIN 100 - both of which suggested harm - should give us caution. Let's discuss....

[Ilker Selcuk MD PhD @ilkerselcukmd]

A great honor. Re-defining the concept of parametrial anatomy, nerve sparing and radical hysterectomy types with our international team of gynecological oncologists and anatomists. 'Radical hysterectomy is the art of pelvic surgery, Ilker Selcuk MD-PhD' @IJGConline @ESGO_society

[20 Minutes @20Minutes]

Si le dépistage reste un examen essentiel pour détecter un cancer du sein, l’auto-palpation est elle aussi recommandée. Comment s'y prendre? On vous explique

[Yakup Ergün @dr_yakupergun]

Excited to share our meta-analysis

💥According to the pooled analysis of the PENELOPE-B, PALLAS, MonarchE and NATALEE trials, there is a significant DFS benefit of CDK 4/6 inhibition, especially in stage 3 patients (HR: 0.67)

https://t.co/D2GLhQLknK

[The Lancet Oncology @TheLancetOncol]

NOW OF: In the final 10-yr survival analysis of the OVHIPEC-1 ph 3 RCT of cytoreductive surgery w/o vs w/ HIPEC in pts with adv ovarian cancer, median PFS was 10·7 months (95% CI 9·6–12·0) vs 14·3 months (12·0–18·5); HR 0·63 [95% CI 0·48–0·83], p=0·0008).

https://t.co/QWlQVN08GP

[Enora Laas-Faron @enoralaas]

An easy, fast, and accurate way for implementing the standards of care for the management of patients with endometrial carcinoma into daily clinical practice: the ESGO mobile app https://t.co/M0r3ROoMCH

[Yakup Ergün @dr_yakupergun]

Platinum‐based chemotherapy for early triple‐negative breast cancer (Cochrane Database)

20 studies, 4.688 patients

DFS and OS (Carbo)⬆️
Neoadj➡️HR: 0.63 and 0.69
Adj➡️HR 0.69 and 0.70

📌 Regardless of BRCA, HRD, LN positivity and anthracycline

https://t.co/UFsMEvobob

[Fumet Jean-David, MD, PhD @jdfumet]

💡 Nouvel outil indispensable en RCP gynéco pour retrouver en quelques clics les recommandations #ESGO et #ESTRO de traitement adjuvant des cancers de l’endomètre

📲 disponible dans [Espace Pro] d’@OncoClic

[Fabio Martinelli @DrFMartinelli]

#ovariancancer: ⁦@myESMO⁩ Clinical Practice Guideline for diagnosis, treatment and follow-up† - ⁦@Annals_Oncology⁩ ⁦@ESGO_society⁩ ⁦@IGCSociety⁩ ⁦@GynMe4⁩ ⁦@gyncsm⁩ ⁦@OncoAlert⁩ ⁦@weoncologists⁩ https://t.co/NQ0MeUEftI

[Anirban Maitra @Aiims1742]

Cancer Statistics 2023 from @AmericanCancer is now published in @CAonline
#OpenAccess
https://t.co/VnC07OigHm
@OncoAlert

[@GynOncJnls @gynoncjnls]

🇨🇦 study finds 9% of patients with endometrial intraepithelial neoplasia had high-intermediate to high-risk disease on final pathology: SLN mapping useful @Gyne_Oncology @SGO_org @IGCSociety @ESGO_society @SOGCorg @OncoAlert @mcgillu https://t.co/4xYmBXj7fy

[Vivek Subbiah, MD @VivekSubbiah]

📢🥁By popular demand presenting the TOP Oncology publications of 2022.

PS: List not exhaustive - so feel free to tag & add important papers to the list @OncoAlert @NEJM @TheLancetOncol @Annals_Oncology @NatureMedicine @Nature @CD_AACR

[Patrick Baud @patrick_baud]

Chaque année, je crée un nouveau document dans lequel je note tous les trucs intéressants que j'apprends au fil des mois. Voici une petite selection de mon doc 2022⬇️

[@GynOncJnls @gynoncjnls]

Oral selinexor in combination with weekly paclitaxel demonstrates promising clinical activity with manageable toxicity in ovarian cancer patients @ShannonWestin @SGO_org @IGCSociety @ESGO_society @ASCO @myESMO @OncoAlert https://t.co/7dteXFzbJQ

[@GynOncJnls @gynoncjnls]

Menopausal estrogen-only therapy associated with 33% lower odds of having macroscopic residual disease following primary cytoreductive surgery🚨What’s the mechanism? 🤨 @SGO_org @IGCSociety @ESGO_society @OncoAlert @ASCO @myESMO https://t.co/3r3tB0GQtB

[Henri Azaïs @HenriAzais]

Robotic pelvic and para-aortic retroperitoneal lymph nodes staging for early-stage epithelial ovarian cancer https://t.co/H4RI2XTFCE

[Dr Raul Pacheco-Vega @raulpacheco]

I am looking for this meme but I can’t find the name of the turtle. What’s their name?

[Enora Laas-Faron @enoralaas]

Major question this morning @SABCSSanAntonio on possibility of breast conserving surgery in multiple tumors.
* 70% of multiple incision
* 5 yrs local recurrence rate : 3.1%
* Interest of preoperative MRI
Promising !

#SABC2022 @SABCSSanAntonio
@OncoAlert